Table 1. Multivariate analysis of prognostic factors for DFS.
Factor | Cox model | ||
---|---|---|---|
HR | 95% CI | P value | |
Age, per increase of 1 yr | 0.71 | 0.43–1.34 | 0.127 |
Sex, men vs. women | 1.01 | 0.93–1.28 | 0.414 |
CLM number, per increase of 1 unit | 0.71 | 0.51–0.81 | 0.312 |
CLM size, per increase of 1 cm | 1.18 | 0.81–1.21 | 0.063 |
Preoperative chemotherapy, yes vs. no | 0.98 | 0.31–1.32 | 0.849 |
CEA level, elevated vs. normal | 1.14 | 0.73–1.35 | 0.073 |
CA19-9 level, elevated vs. normal | 1.31 | 1.58–2.61 | 0.061 |
T of the primary tumor, T3-4 vs. T1-T2 | 0.31 | 0.12–0.99 | 0.789 |
N of the primary tumor, positive vs. negative | 1.01 | 0.49–1.29 | 0.071 |
Synchronous vs. metachronous presentation | 0.88 | 0.76–2.11 | 0.061 |
Grading of primary tumor, G1-2 vs. G3-4 | 1.19 | 0.18–1.81 | 0.097 |
RAS status, mutated vs. wild-type | 0.98 | 0.19–1.31 | 0.739 |
Liver involvement, bilateral vs. unilateral | 1.01 | 0.67–1.14 | 0.076 |
Site of the primary tumor, right vs. left | 0.79 | 0.51–1.56 | 0.364 |
TAMs area, L-TAM vs. S-TAM | 3.41 | 1.13–5.43 | 0.001 |
CA 19-9, cancer antigen 19-9; CEA, carcinoembryonic antigen; T, tumor, N, node; RAS, RAS gene.